Midatech Pharma PLC (LON:MTPH)

Midatech Pharma PLC (LON:MTPH)


Share Price
6.75 p
Change
-1.25 (-15.63 %)
Market Cap
£27.63 m
Proactive Investors - Run By Investors For Investors

Midatech Pharma PLC

Midatech is fully focussed on enhancing and extending the lives of patients with rare and serious cancers. We have built an organization distinguished by world-class scientists with a talent for developing and applying our novel drug delivery technologies to improve existing, or develop new, treatments for these diseases. Our driving  philosophy is to seize scientific and clinical...

EPIC: MTPH
Market: AIM:MTPH
52-week High/Low: 39.196p / 2.450p
Sector: Pharmaceuticals
Market Cap: £27.63 m
Website: www.midatechpharma.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Midatech Pharma PLC


Midatech Pharma PLC Snapshot

Midatech Pharma is focused on the research and development of medicines for rare cancers, via both in house programmes as well as partnered programmes.  We develop improved chemo~therapeutics or new immuno~therapeutics, using our proprietary platform drug delivery technologies.

  • Q-Sphera™ platform: our disruptive polymer microsphere technology is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months.
  • Midasolve platform: our innovative nanosaccharide technology is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumours
  • Midacore™ platform: our leading edge gold nanoparticle technology is used for targeting sites of disease at the nanoscale ie i. chemotherapy - improved and targeted delivery of existing chemotherapeutic agents to tumour sites, as well as ii. immunotherapy - enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells

All our technologies are thus focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can exert their actions in an effective, safe and precise manner.

In this way Midatech’s objective is to address lethal diseases that otherwise may not be possible, or very difficult.

Our blueprint for success in the years ahead is inspired by developing and advancing our treatments and platform technologies, via in house programmes as well as in collaboration with partners, that will make a difference for patients and  healthcare workers, and create value for payers, and our shareholders.

R&D Overview

Each of our technologies are in the clinic, each with its own live clinical program, and each with opportunities beyond current programs

Midatech is a forerunner in the science and development of drug delivery technologies providing a source of therapies for patients suffering from rare diseases with limited treatment options.

Midatech has established a strong and differentiated pipeline and are delivering in our strategy to develop franchises in oncology and immunotherapy, based on our state-of-the-art drug delivery technologies to generate improved as well as new medicines for rare and serious cancers.

The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The Q-Sphera™ sustained release technology platform, with numerous and distinct advantages over traditional polymer microsphere production, utilizes precisely and consistently manufactured monodispersed micro particles such that active drug compounds are released into the body in a tightly controlled manner over an extended period of time (e.g., weeks to months) The MidaCore™ gold nanoparticle technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use. They are composed of a core of gold atoms surrounded by a layer of carbohydrates and linkers for attachment of small molecules (e.g., chemotherapeutics, peptides, etc.) and targeting agents. The small size and multivalency arrangement around the gold core underpin the ability to improve biodistribution and thus safety and efficacy of existing drugs. Midatech’s MidaSolve technology is utilized for potent small molecule chemotherapeutics that have minimal solubility at biological pH, which limits them to oral administration. When reformulated with the MidaSolve technology, the complexed molecules solubilize such that parenteral routes of administration can be employed. This enables local administration directly into the tumour.


Technologies

Midatech has three platform technologies that are focused on improving bio-distribution and bio-delivery of medications in different ways – either via sustained delivery, targeted delivery, or direct delivery.

Q-Sphera

Sustained delivery is achieved using our polymer microsphere technology Q-Sphera™, which is based on our disruptive micro-piezo print production inovation to individually print drug-loaded microspheres in the size range 20-50µm, at a rate of several million spheres per second. Microsphere dimensions are consistently monodispersed and homogenous, and can be thus be finely tuned to accurately customise drug release rates. Reliable and precise encapsulation enables drug release into the body in a highly controlled and predictable manner over a prolonged period of time, from a few weeks to more than six months. Q-Sphera microspheres have improved injectability characteristics compared to traditional manufacturing methods, requiring a much simpler, error free and shorter reconstitution process. The monodispersed particles avoid needle blockage, and facilitate the use of smaller gauge needles with reduced injection pain. Q-Sphera formulations typically yields consistent and reproducible blood and local tissue drug concentrations within tight limits.

MidaSolve

Direct delivery is achieved using our nano saccharide technology MidaSolve, which effectively allows insoluble medications to be converted from a solid tablet form for oral ingestion, to a dissolved liquid form that can then be infused directly into the tumour. The N-Circ complexes are particularly stable, with a significant increase in the aqueous solubility of the compound at biological pH. The technology increases the possible routes of administration and uses from an oral only route to a liquid form that can be given parenterally into the body or tumour directly.

MidaCore

Targeted delivery is achieved using our gold nanoparticle technology MidaCore®, a leading innovation in ‘ultra-small’ nanomedicine, enabling improved delivery of therapeutics to tumor cells and the immune system. In oncology treatments MidaCore® provides a nano complex (less than 5nm in size) that carries conventional small molecule chemo-therapeutic payloads and delivers these to the tumour site in high concentrations. In immune-oncology treatments, MidaCore acts as a nano carrier complex for synthetic immuno-peptides to seek out cancer cell-surface proteins via immune mediated peptide vaccines. These small complexes can enter immune processing cells to induce T-cell mediated immune responses specifically against tumour cells, viral infected host cells or autoimmune disease.


 

United Kingdom.

Name Number of shares %
Woodford Investment Management 12,247,629 20.1
Legal & General Group

10,275,518

16.8
City Financial 3,650,000 6.0
Wings Establishment 3,043,164 5.0
Hargreave Hale 2,992,585 4.9
     
Midatech Pharma Share Incentive Plan 105,068 n/a

 

Midatech Pharma Plc

Craig Cook, Chief Executive Officer
Nick Robbins-Cherry, Finance Director
Tel: +44 (0)1235 888300
Email: [email protected]

Registered Office and Trading Address:
Oddfellows House
19 Newport Road
Cardiff
CF24 0AA
United Kingdom

IFC Advisory

Graham Herring, Tim Metcalfe, Heather Armstrong
Tel: +44 (0)203 934 6633
Email: [email protected]

Nominated Adviser and Broker

Panmure Gordon (UK) Limited
One New Change
London
EC4M 9AF
United Kingdom
+44 (0)20 7886 2500

Financial Public Relations & Investor Relations (UK)

IFC Advisory
24 Cornhill
London
EC3V 3ND
United Kingdom
+44 (0)203 934 6633
[email protected]

Investor Relations (US)

Westwicke Partners, Boston, US
Westwicke Partners, Boston, US
132 Chief Justice Cushing Highway
Cohasset
MA 02025
+001 (339) 970-2843

Solicitors

Brown Rudnick LLP
8 Clifford Street
London
W1S 2LQ
United Kingdom

Reporting Accountants and Auditors

BDO LLP
55 Baker Street
London
W1U 7EU
United Kingdom

Registrars

Neville Registrars Limited
Neville House
Steelpark Road
Halesowen
B62 8HD
United Kingdom
+44 (0)121 585 1131
[email protected]

Columns Including MTPH

VIEW ALL

Market Reports Including MTPH

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use